Bionomics Limited engages in the discovery and development of therapeutics in the areas of cancer, multiple sclerosis, anxiety, and epilepsy in Australia and France. Technologies MultiCore MultiCore technology is a suite of methods for the chemical synthesis of complex drug-like molecules with ring structures that is the structure of many marketed drugs, and naturally occurring bioactive molecules. The company applies its MultiCore technology to the production of compound libraries in this complex molecular space that focus on the target of interest and are weighted towards drug-like characteristics. Angene: Proprietary technology behind BNC105 The company’s drug discovery platform Angene incorporates a variety of tools and models of angiogenesis (the formation of new blood vessels) for drug target validation and drug discovery in cancer and inflammation. IonX IonX is an integrated platform of genomics discoveries and technologies that serves as the foundation for Bionomics' CNS drug discovery and development activities. IonX includes systems for high throughput electrophysiology for early, high content evaluation of drug hits. Collaborations/Partnerships Bionomics’ Merck Serono partnership: Bionomics’ Merck Serono partnership is a fully funded collaboration, covered by an R&D and licensing agreement. The collaboration represents the validation of Bionomics’ chemistry platform, Multicore, and know how in ion-channel biology, covered by the company’s IonX technology. Bionomics subsidiary Neurofit is also active in the collaboration with Merck Serono. The partnership involves the preclinical development of Kv1.3 as a target for the treatment of multiple sclerosis. Cancer Therapeutics Co-operative Research Centre: The company is a participant and shareholder of the Cancer Therapeutics Co-operative Research Centre (CTx). CTx is focused on the discovery and early development of small molecule drugs for the treatment of cancer. CTx has a specific focus on small molecule cancer drugs or enabling therapeutics for single or co-therapy regimes.
(BNO:Australian Stock Exchange Ltd)
31 Dalgleish Street
Thebarton, SA 5031
Phone: 61 8 8354 6100
Fax: 61 8 8354 6199www.bionomics.com.au
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content.
|No competitor information is available for BNO.|
|View Industry Companies|
|Price/Cash Flow||NM||Not Meaningful|
Sponsored Financial Commentaries
To contact BIONOMICS LTD, please visit www.bionomics.com.au. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.